Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- N/A.
M&A news:
- SHPG +2.2% (Sky News details that activists want Shire (SHPG) to be broken up)
- HSY +0.8% (reports that the company will be among bidders for Nestle's (NSRGY) confectionery unit)
Select metals/mining stocks trading higher:
- FCX +3.3%, CLF +2.8%, AKS +2.1%, BHP +1.9%, RIO +1.8%, BBL+1.1%, VALE +1%
Other news:
- TRXC +80.8% (FDA clears new robotically-assisted surgical device for adult patients)
- IBIO +30% (agreement with Aethlon Medical (AEMD) to support potential large-scale production of the Aethlon Hemopurifier blood purification device)
- LBIX +23.3% (continued strength)
- AGLE +21.4% (enters into clinical collaboration agreement with Merck)
- EXEL +18.2% (announces phase 3 CELESTIAL trial met its primary endpoint; FDA granted priority review to the sNDA for CABOMETYX)
- PETX +11.2% (announces they are making ENTYCE commercially available to veterinarians in the United States for appetite stimulation in dog)
- FENC +8.8% (announces data from its Phase 3 SIOPEL 6 study presented during the late breaker session on Saturday, October 14)
- VHC +8.6% (reportedly being awarded $344 mln from Apple (AAPL) dispute)
- CARA +4.7% (announces the successful completion of its End-of-Phase 2 Meeting with the FDA)
- ZKIN +3.9% (signs a $2 mln initial pipeline infrastructure contract with Huawei)
- EBIO +3.8% (appoints Richard Fitzgerald as Interim CFO effective October 20)
- KURA +3.3% (still checking)
- JD +3.1% (Barron's profiles positive view on JD.com)
- GORO +3.1% (reports prelim 3Q17 production)
- IMGN +3% (FDA has completed the safety review of its IND for IMGN632 in patients with CD123-positive hematological malignancies; co plans to open a Phase 1 study to enrollment before the end of the year)
- CATB +2.9% (entered Sales Agreement with Cowen to offer up to $10 mln of common stock)
- INO +2.2% (initiates phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche's atezolizumab (TECENTRIQ) in combination with Inovio's INO-5401), .
Analyst comments:
- XXII +8.2% (target raised to $11.50 at Chardan Capital Markets)
- CELC +6.2% (initiated with a Buy at Craig Hallum)
- AU +5.9% (upgraded to Overweight from Neutral at JP Morgan)
- ABEO +4.4% (target raised to $30 at H.C. Wainwright)
- BSTI +4% (initiated with a Buy at Goldman)
- GRPN +3% (upgraded to Market Perform from Underperform at Cowen)
- INFN +1.4% (upgraded to Neutral from Sell at Citigroup)
- AAPL +0.8% (upgraded to Overweight from Sector Weight at Pacific Crest)
- NVDA +0.7% (target raised to $220 from $180 at Mizuho)
- AZN +0.5% (upgraded to Outperform from Neutral at Credit Suisse)